Pioneering Neuroprotection and Regeneration for Neurodegenerative Diseases and Disorders
Genervon is a closely held, clinical-stage biopharmaceutical company that is pursuing a new paradigm of drug discovery in the belief that multi-target drug development is the key to curing complex neurological disorders. Genervon discovered a naturally occurring regulator of the development of the human nervous system and has developed and synthesized a cationic, cell-penetrating peptide analog of that regulator. This peptide, which Genervon calls GM6, passes through the human blood-brain barrier and is safe and well-tolerated—as one would expect from a compound endogenous to human biology. GM6 also has been shown to modulate key biomarkers and multiple defective pathways associated with neurodegenerative disorders and to improve clinical outcomes for patients.
Genervon holds more than 80 patents worldwide and is currently planning late-stage clinical trials for GM6 for ALS, PD, AD and MS indications.
Recognizing the lack of curative therapies for patients suffering from neurodegenerative diseases and disorders, Genervon has devoted the last twenty years to research and development in pursuit of a cure.
Genervon’s innovation is in using a master regulatory approach to target the common underlying pathophysiology of neurodegenerative diseases and disorders and their multiple pathways and genes.
After 20 years of funding its own research and operations, Genervon is now actively seeking partners to help advance GM6 from a development-stage drug candidate to a marketable therapy for the many victims of neurodegenerative diseases and disorders that desperately need help.